Measurement of treatment efficacy and new trial results in multiple sclerosis

Current Opinion in Neurology

Volumn 10, Issue 3, 1997, Pages 201-210

  Noseworthy, John H ^a   Miller, David H ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA2A INTERFERON; AZATHIOPRINE; BETA1A INTERFERON; CLADRIBINE; GLATIRAMER; IMMUNOGLOBULIN; METHOTREXATE; MYELIN BASIC PROTEIN; NEUTRALIZING ANTIBODY; RECOMBINANT BETA INTERFERON; ROQUINIMEX; STEROID;

BLOOD BRAIN BARRIER; DISEASE COURSE; HUMAN; MEASUREMENT; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; RELAPSE; REVIEW; TRAINING; TREATMENT OUTCOME;

EID: 0030792472     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199706000-00006     Document Type: Review

References (58)

1. The IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:655-661.
2. Paty DW, LI DKB: the UBC MS/MRI Study Group, and the IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:662-667.
3. IFNB Multiple Sclerosis Study Group, University of British Columbia MS MRI Analysis Group: Interferon beta-1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology 1995, 45:1277-1276.
4. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995, 45:1268-1276.
5. Whitaker JN, McFarland HF, Rudge R, Reingold SC: Outcome assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1995, 1:37-47.
6. Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S, Lublin FD, Paty DW, Reingold SC, Simon J: Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996, 39:6-16.
7. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH et al.: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol 1996, 39:285-294.
8. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BG, Burks JS: Management of patients receiving interferon beta 1b for multiple sclerosis: report of a consensus conference. Neurology 1996, 46:12-18.
9. Paty DW, Goodkin D, Thompson A, Rice G: Guidelines for physicians with patients on IFN b-1b: the use of an assay for neutralizing antibodies (NAB). Neurology 1996, 47:865-866.
10. IFNB Multiple Sclerosis Study Group of the University of British Columbia MS MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon b-1b: experience during the first three years. Neurology 1996, 47:889-894.
11. Hughes RAC, Sharrack B: More immunotherapy for multiple sclerosis. J Neurol Neurosurg Psychiatry1996, 61:239-241.
12. Lublin FD, Reingold SC: National Multiple Sclerosis Society (USA). Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996, 46:900-911.
13. Kurtzke JF: Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
14. Weinshenker BG, Issa M, Baskerville J: Long-term and short-term outcome of multiple sclerosis: a 3-year follow-up study. Arch Neurol 1996, 53:353-358.
15. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC: The natural history of multiple sclerosis: a geographically based study, I. Clinical course and disability. Brain 1989, 112:133-146.
16. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, Ebers GC: The natural history of multiple sclerosis: a geographically based study, II. Predictive value of the early clinical course. Brain 1989, 112:1419-1428.
17. Weinshenker BG, Rice GPA, Noseworthy JH, Carriere W, Baskerville J, Ebers GC: The natural history of multiple sclerosis: a geographically based study, III. Multivariate analysis of predictive factors and models of outcome. Brain 1991, 114:1045-1056.
18. Weinshenker BG, Rice GP, Noseworth J, Carriere W, Baskerville J, Ebers GC: The natural history of multiple sclerosis: a geographically based study, IV. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991, 114:1057-1067.
19. Koziol JA, Frutos A, Spie JC, Romine JS, Beutler E: A comparison of two neurologic scoring instruments for multiple sclerosis. J Neurol 1996, 243:209-213.
20. Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, Chang C. Lloyd S, Steward J, Stefoski D: Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996, 47:129-139.
21. Sharrack B, Hughes RAC: Clinical scales for multiple sclerosis. J Neurol Sci 1996, 135:1-9.
22. Schwartz CE, Coulthard-Morris L, Zeng Q, Retzlaff P: Measuring self-efficacy in people with multiple sclerosis: a validation study. Arch Phys Med Rehab 1996, 77:394-398.
23. Stone L, Frank JA, Albert PS, Bash C, Smith ME, Maloni H, McFarland HF: The effect of beta interferon on blood brain barrier disruptions demonstrated by contrast enhanced MRI in relapsing remitting multiple sclerosis. Ann Neurol 1995, 37:611-619.
24. Moreau T, Thorpe J, Miller D, Moseley I, Hale G, Waldmann H, Clayton D, Wing M, Scolding N, Compston A: Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 1994, 334:298-301.
25. Van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bereismann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH: Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumour necrosis factor antibody CA2. Neurology 1996, 47:1531-1534.
26. Paolino E, Fainardi E, Ruppi P, Tola MR, Govoni V, Casetta I, Monetti VC, Gramen E, Carreras M: A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. J Neurol Neurosurg Psychiatry 1996, 60:572-575.
27. Martinelli V, Rodegher M, Filippi M, Rovaris M, Campi A, Colombo B, Comi G: Brain MRI follow-up of patients with persistent isolated optic neuritis. Eur J Neurol 1996, 3:36-39.
28. Filippi M, Yousry T, Campi A, Kandziora C, Colombo B, Voltz R, Martinelli V, Spuler S, Bressi S, Sccotti G, Comi G: Comparison of triple dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 1996, 46:379-384.
29. Silver NC, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, Miller DH: Enhancing lesion detection in multiple sclerosis: effects of gadolinium dose, magnetisation transfer and delayed scanning [Abstract]. Eur J Neurol 1999, 3(suppl 4): 10.
30. Filippi M, Yousry T, Baratti C, Horsfield MA, Mammi S, Becker C, Voltz R, Spuler S, Campi A, Reiser MF, Comi G: Quantitative assessment of MRI lesion load in multiple sclerosis; a comparison of conventional spin echo with fast fluid attenuated inversion recovery. Brain 1996, 119:1349-1355.
31. Stevenson VL, Gawne-Cain ML, Barker GJ, Thompson AJ, Miller DH: Imaging of the spinal cord and brain in multiple sclerosis: a comparative study between fast flair and fast spin echo. J Neurol 1997, 244:119-124.
32. Losseff NA, Webb SL, O'Riordan JI, Page R, Wang L, Barker GJ, Tofts PS, McDonald WI, Miller DH, Thompson AJ: Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996, 119:701-708.
33. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne-Cain ML, McDonald WI, Miller DH, Thompson AJ: Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996, 119:2009-2019.
34. Truyen L, Van Waesberghe JHTM, Van Walderveen MAA, van Oosten BW, Polman CH, Hommes OR, Ader HJ, Barkhof F: Accumulation of hypointense lesions ("black holes") on T1 spin echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996, 47:1469-1476.
35. Pozzilli C, Bastianeoll S, Koudriavtseva T, Gasperini C, Bozzao A, Millefiorini E, Galgani S, Buttinelli C, Perciaccante G, Piazza G et al.: Magnetic resonance imaging changes with recombinant human interferon beta 1a: a short-term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996, 61:251-258.
36. Khan OA, Xia Q, Bever CT Jr, Johnson KP, Panitch HS, Dhib-Jalbut SS: Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology 1996, 46:1639-1643.
37. Rieckmann R, Weber F, Gunther A, Poster S: The phosphodlesterase inhibitor pentoxifylline reduces early side effects of interferon ab-1b treatment in patients with multiple sclerosis. Neurology 1997, 47:604.
38. Durelli L, Bongioanni MR, Ferrero B, Ferri R, Imperiale D, Bradac GB, Bergui M, Geuna M, Bergamini L, Bergamasco B: Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment. Neurology 1996, 47:123-129.
39. Korczyn AD, Nisipeanu P: Safety profile of coplymer-1: analysis of cumulative experience in the United States and Israel. J Neurol 1996, 243(suppl 1):S23-S26.
40. Mancardi GL, Sardanelli F, Parodi RC, Melani E, Cupello E, Inglese M, Fererari A, Sormani MP, Ottonello C, Levrero F et al.: The effect of copolymer-1 on serial gadolinium enhanced magnetic resonance scans in relapsing remitting multiple sclerosis [Abstract]. Eur J Neuorol 1996, 3(suppl 4):33.
41. Beutler E, Sipe JC, Rommie JS, Koziol JA, McMillan R, Zyroff J: The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 1996, 93:1716-1720.
42. Sipe JC, Romine JS, Koziol JA, McMillian R: Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994, 334:9-13.
43. Goodkin DE, Rudick RA, VanderBrug MS, Daughtry MM, Van Dyke C: Low-dose oral methotrexate in chronic progressive multiple sclerosis. Neurology 1996, 47:1153-1157.
44. Goodkin DE, Rudick RA, Vanderbrug MS, Daughtry MM, Schwetz KM, Fischer J, Van Dyke C: Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995, 37:30-40.
45. Olek MJ, Hohol MD, Weiner HL: Methotrexate in the treatment of multiple sclerosis [Letter]. Ann Neurol 1996, 39:684.
46. Sorensen PS, Wanscher B, Szpirt W, Jensen CV, Ravnborg M, Christiansen P, Schreiber K, Nordenbo A: Plasma exchange combined with azathloprine in multiple sclerosis using serial gadolinium-enhance MRI to monitor disease activity: a randomized single-masked cross-over pilot study. Neurology 1996, 46:1620-1625.
47. Confavreux V, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G: Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 1996, 46:1607-1612.
48. Hahn JS, Siegler OJ, Enzmann D.: Intravenous gammaglobulin therapy in recurrent acute disseminated encephalomyelitis. Neurology 1996, 46:1173-1174.
49. Lycke J, Svennerholm B, Hjelmquist E, Frisen L, Badr G, Andersson M, Vahlne A, Anderson O: Acyclovir treatment of relapsing-remitting multiple sclerosis: a randomized, placebo-controlled, double-blind study. J Neurol 1996, 243:214-224.
50. Andersen O, Lycke J, Tollesson PO, Svenningsson A, Runmarker B, Linde AS, Astrm M, Gjorstrup P, Ekholm S: Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996, 47:895-900.
51. Karussis DM, Meiner Z, Lehmann D, Gomori JM, Schwarz A, Linde A, Abramsky O: Treatment of secondary progressive multiple sclerosis with the immunomodulator Llnomide; a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 1996, 47:341-346.
52. Warren KG, Katz I: Administration of myeline basic protein synthetic peptides to multiple sclerosis patients. J Neurosci 1995, 133:85-94.
53. Rosenberg GA, Dencoff JE, Correa Jr N, Reiners M, Ford CC: Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis. Neurology 1996, 39:1626-1632.
54. Petajan JH, Gappmaier E, White AT, Spencer MK, Mino L, Hicks RW: Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996, 39:432-441.
55. Johnson B: Exercise, drug treatment and the optimal care of multiple sclerosis patients. Ann Neurol 1996, 39:422-423.
56. Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB: The effects of Amantadine and Pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 1996, 53:185-188.
57. Mattson D, Petrie M, Stivastava DK, McDermott M: Multiple sclerosis: sexual dysfunction and it's response to medications. Arch Neurol 1995, 52:862-868.
58. Azouvi P, Mane LM, Thiebaut JB, Denys P, Remy-Neris O, Bussel B: Intrathecal Baclofen administration for control of severe spinal spasticity: Functional improvement and long-term follow-up. Arch Phys Med Rehab 1996, 77:35-39.